Sibel Ozdemir | Pharmacology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Sibel Ozdemir — Yunus Emre State Hospital, Turkey

Sibel Ozdemir
Affiliation Yunus Emre State Hospital
Country Turkey
Scopus ID 60749146700
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0009-0003-4671-0964

Sibel Ozdemir is a researcher associated with Yunus Emre State Hospital whose recent scholarly work connects neurology with pharmacological investigation. Published studies have examined antiseizure medicines, experimental seizure models, medication combinations, and potential interactions involving clopidogrel, valproic acid, and levetiracetam. [1] [2]

Abstract

Sibel Ozdemir is a researcher affiliated with Yunus Emre State Hospital in Turkey whose documented work addresses pharmacology, neurology, and experimental seizure research. Her recent publications examine interactions between antiplatelet and antiseizure medicines and pharmacological effects in experimental models. This profile summarizes her research themes, publications, and recognition context in research.

Keywords

Epilepsy, valproic acid, levetiracetam, clopidogrel, pentylenetetrazol, freezing behavior, antiseizure medicines, anticonvulsant efficacy, experimental seizure models, behavioral effects, drug interactions, neurology, pharmacology, and clinical pharmacology. These terms reflect the themes identified in her recent research publications. [1] [2]

Introduction

Sibel Ozdemir is affiliated with the Department of Neurology at Yunus Emre State Hospital, Eskişehir, Türkiye. Her recent scholarly record includes investigations involving antiseizure medicines, drug interactions, and neurological models. These studies connect clinical neurology with pharmacological questions concerning treatment combinations and biological responses in experimental research settings. [1] [2]

Research Profile

Sibel Ozdemir’s documented research profile centers on neurology and pharmacology, with publications involving antiseizure therapy, experimental seizure models, and medication interactions. PubMed records identify her ORCID as 0009-0003-4671-0964 and associate recent work with Yunus Emre State Hospital. The available evidence supports a clinically oriented pharmacological research profile in clinical practice. [1]

Research Contributions

Sibel Ozdemir contributes to research examining pharmacological effects in neurological conditions. A 2026 study evaluated clopidogrel alongside valproic acid and levetiracetam in a pentylenetetrazol-induced seizure model, while another study examined differential effects of valproic acid and levetiracetam on freezing behavior. These studies address medication efficacy and drug interactions in pharmacology. [1] [2]

Publications

Sibel Ozdemir is listed as an author on publications concerning antiseizure pharmacology and neurological experimental models. Her 2026 International Journal of Molecular Sciences article investigated clopidogrel with valproic acid and levetiracetam, while a 2026 Journal of Biotechnology and Strategic Health Research article examined valproic acid and levetiracetam effects in rats. [1] [2]

Research Impact

Sibel Ozdemir’s research has potential relevance to pharmacological decision-making by investigating how neurological medicines behave in experimental combinations. The documented studies provide evidence about antiseizure efficacy and medication interactions, while their experimental designs also illustrate translational questions that may require further clinical investigation before broader conclusions are drawn. [1] [2]

Award Suitability

Sibel Ozdemir’s publication activity aligns with an Innovative Research Award profile through its focus on pharmacological questions in neurological research and experimental models. The publications demonstrate investigation of drug combinations and antiseizure effects. Award recognition should consider originality, methodological contribution, publication record, and relevance of the submitted research evidence overall. [1] [2]

Conclusion

Sibel Ozdemir’s available scholarly record presents a research trajectory connecting clinical neurology with pharmacology and experimental seizure research. Her recent publications provide documented evidence of work on antiseizure medicines and drug interactions. Continued publication, independent validation, and clinical translation would further clarify the broader significance of these research contributions today. [1] [2]

References

    1. Özdemir, S., Bolayır, E., & Şahin İnan, Z. D. (2026). Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model. International Journal of Molecular Sciences, 27(14), 6415.
      https://doi.org/10.3390/ijms27146415
    2. Gürkan, İ. M., Demir Cevizlidere, B., Çalişkan, S., Özdemir, S., & Özdemir, H. (2026). Effects of nano-hydroxyapatite-coated PRF on gingiva-derived mesenchymal stem cells: In vitro study. International Journal of Molecular Sciences, 27(13), 5736.
      https://doi.org/10.3390/ijms27135736
    3. ORCID. (n.d.). ORCID record: Sibel Ozdemir, ORCID 0009-0003-4671-0964.
      https://orcid.org/0009-0003-4671-0964
    4. Elsevier. (n.d.). Scopus author details: Sibel Ozdemir, Author ID 60749146700. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=60749146700

Said Moshawih | Pharmacology | Best Researcher Award

Published on by Health Scientists
Said Moshawih
Affiliation Al-Ahliyya Amman University
Country Jordan
Scopus ID 57209745538
Documents 42
Citations 998
h-index
17
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0000-0003-4840-0460

Best Researcher Award

Said Moshawih is an academic researcher specializing in pharmacology, medicinal plants, natural products, phytochemistry, pharmaceutical sciences, and evidence-based herbal medicine. His research integrates laboratory investigations with systematic scientific reviews to evaluate bioactive compounds, therapeutic mechanisms, and translational healthcare applications. His scholarly publications have contributed to understanding herbal pharmacology, cardiovascular protection, antimicrobial activities, antioxidant mechanisms, and functional medicinal plants while supporting innovation in pharmaceutical research and healthcare advancement.[1]

Abstract

Said Moshawih has established an internationally recognized research portfolio in pharmacology through multidisciplinary investigations involving medicinal plants, phytochemistry, pharmaceutical sciences, cardiovascular health, antimicrobial agents, antioxidant compounds, and evidence-based herbal medicine. His publications emphasize translating traditional medicinal knowledge into scientifically validated therapeutic applications while encouraging sustainable healthcare innovation. Through collaborations, systematic reviews, experimental pharmacology, and natural product research, his work has strengthened pharmaceutical development, improved understanding of bioactive compounds, supported clinical relevance, and contributed valuable scientific evidence for advancing modern healthcare practices and future pharmacological discoveries.[2]

Keywords

Medicinal plants, Pharmacology, Phytochemistry, Herbal medicine, Natural products, Antioxidants, Cardiovascular health, Antimicrobial activity, Ethnopharmacology, Functional foods, Bioactive compounds, Pharmaceutical sciences, Toxicology, Drug discovery, Plant extracts.

Introduction

Said Moshawih investigates medicinal plants and pharmaceutical sciences by integrating pharmacological evidence with phytochemical characterization. His research supports safe therapeutic development, explores natural bioactive compounds, and promotes evidence-based herbal medicine for improving disease prevention, healthcare quality, and future pharmaceutical innovation through multidisciplinary scientific collaboration worldwide.[3]

Research Profile

Said Moshawih maintains an active international research profile with publications spanning pharmacology, medicinal chemistry, pharmaceutical technology, herbal therapeutics, and systematic scientific reviews. His collaborative investigations have generated influential literature supporting translational medicine while encouraging innovation across academic, clinical, and pharmaceutical research environments globally.[1]

Research Contributions

Said Moshawih has contributed significantly to understanding phytochemicals, herbal pharmacology, antioxidant mechanisms, cardiovascular protection, antimicrobial compounds, and pharmaceutical formulations. His research strengthens scientific validation of medicinal plants while encouraging interdisciplinary collaborations that bridge laboratory discoveries with practical healthcare applications and therapeutic innovations.[4]

Publications

Said Moshawih has authored numerous highly cited publications covering medicinal plants, coriander pharmacology, herbal cardiovascular benefits, antimicrobial phytochemicals, colorectal cancer prevention, pharmaceutical sciences, and evidence-based natural medicine. These publications demonstrate sustained scholarly productivity, interdisciplinary collaboration, and consistent contributions to international scientific literature.[2]

Research Impact

Said Moshawih’s research has influenced pharmaceutical sciences by providing comprehensive evidence supporting medicinal plants and natural therapeutics. His publications receive substantial academic recognition through citations, demonstrating meaningful impact on pharmacological research, healthcare innovation, systematic reviews, and future evidence-based therapeutic development internationally.[1]

Award Suitability

Said Moshawih demonstrates strong qualifications for the Best Researcher Award through impactful publications, substantial citation performance, international collaborations, and continuous advancement of pharmacological knowledge. His scientific achievements reflect excellence in research quality, innovation, scholarly influence, and contributions benefiting healthcare and pharmaceutical sciences.[1]

Conclusion

Said Moshawih continues advancing pharmacology through innovative investigations involving medicinal plants, pharmaceutical sciences, and natural products. His sustained scholarly productivity, collaborative research, and evidence-based scientific contributions reinforce his reputation as a respected researcher supporting future developments in healthcare, therapeutic innovation, and pharmaceutical research worldwide.[2]

References

  1. Elsevier. (n.d.). Scopus Author Details: Said Moshawih, Author ID 57209745538. Scopus.
    https://www.scopus.com/pages/authors/57209745538
  2. ResearchGate. (n.d.). Research Profile of Said Moshawih.
    https://www.researchgate.net/profile/Said-Moshawih
  3. ORCID. Said Moshawih Research Profile.
    https://orcid.org/0000-0003-4840-0460
  4. Google Scholar. Said Moshawih Citation Profile.
    https://scholar.google.com/citations?user=_eqg7H4AAAAJ&hl=en&oi=ao
  5. Al-Ahliyya Amman University. Faculty Profile: Said Moshawih.
    https://www.ammanu.edu.jo/staff-directory/faculty-of-pharmacy/said-moshawih/

Raphael Duval | Pharmacology | Research Excellence Award

Published on by Health Scientists

Prof. Dr. Raphael Duval | Pharmacology | Research Excellence Award

Dean | Université de Lorraine | France

Raphaël E. Duval is a senior academic leader and clinical microbiologist serving as Professor and Dean of the Faculty of Pharmacy at Université de Lorraine, France. His expertise spans infectiology, virology, cellular biology, and pharmaceutical sciences, with a strong focus on the discovery and development of innovative anti-infective and anticancer therapeutic agents. His research is widely disseminated through international peer-reviewed journals, scholarly book chapters, patents, and invited scientific communications, reflecting significant academic influence and citation impact. He actively collaborates with multidisciplinary teams across academia and industry at national and international levels. Recognized through prestigious scientific awards and fellowships, his work contributes to advancing therapeutic innovation, strengthening infectious disease management, and addressing major public health challenges with meaningful societal and clinical impact. He has 4909 citations from 98 documents with an h-index of 34.

Citation Metrics (Scopus)

4909
3500
2000
1000
0

Citations

4,909

Documents

98

h-index

34

Citations

Documents

h-index

View Google Scholar Profile
 View Scopus Profile
 View Orcid Profile

Featured Publications

Sipping Kemegne Marius Tresor | Pharmacology | Best Researcher Award

Published on by Health Scientists

Dr. Sipping Kemegne Marius Tresor | Pharmacology | Best Researcher Award

Research scholar | Slovak Academy of Sciences | Slovakia

Dr. Sipping Kemegne Marius Tresor is a biochemist and postdoctoral research fellow whose expertise spans immunopharmacology, cancer biology, inflammatory diseases, and phytomedicine, with a focus on natural bioactive compounds and their translational therapeutic applications. Trained at leading institutions across Africa and Europe, he has developed a strong multidisciplinary foundation integrating molecular biology, pharmacology, biotechnology, and clinical research principles to advance innovation in precision therapeutics. His research has pioneered the exploration and characterization of polysaccharide-rich bioactive fractions from medicinal fungi, particularly Ganoderma species, elucidating their antioxidant, anti-inflammatory, and anti-metastatic potentials and offering promising chemopreventive and therapeutic leads for cancer and immune-mediated disorders. His scientific contributions include peer-reviewed publications in internationally indexed journals and authorship of a scholarly book, demonstrating sustained commitment to advancing biomedical knowledge and global research excellence. Dr. Sipping’s work has been strengthened through impactful collaborations across Africa, Europe, and Asia with prominent scientists and international research groups, fostering interdisciplinary partnerships and capacity building in natural product research and immunotherapeutics. His ongoing investigations focus on isolating novel polysaccharides and developing nanotechnology-enabled drug delivery systems to enhance therapeutic efficacy against chronic inflammatory conditions, such as rheumatoid arthritis, bridging traditional bioresources with cutting-edge biomedical strategies. Beyond laboratory research, he is a certified clinical research professional committed to strengthening translational pathways from preclinical discovery to potential clinical application. His membership in distinguished scientific bodies reflects his dedication to contributing to the global research community. Driven by the vision to harness bioresources and advanced biotechnology for improved public health, Dr. Sipping aims to deliver innovative, accessible, and safe therapeutic options addressing cancer, autoimmune, and infectious diseases, thereby contributing to scientific progress and societal well-being. He has 81 citations from 9 documents with an h-index of 5.

Profiles:  Scopus | ORCID

Featured Publications

1. Sipping, M., Thakur, D., Singh, B., Njamen, D., & Mukherjee, S. (2025). Polysaccharide extract of Ganoderma resinaceum restricts breast cancer progression in vitro by intervening in epithelial–mesenchymal transition and cancer stemness. Revista Brasileira de Farmacognosia.

2. Sipping, M., Sathish Kumar, T., & Kamdem, N. (2025). Scientific investigation on antibacterial, antioxidant, cytotoxic effects and TLC bioautography of Terminalia schimperiania stem bark extracts. Journal of Complementary and Integrative Medicine.

3. Kamga Silihe, K., Defo Mbou, W., Ngo Pambe, J. C., Kenmogne, L. V., Fotso Maptouom, L., Kemegne Sipping, M. T., Zingue, S., & Njamen, D. (2023). Comparative anticancer effects of Annona muricata Linn (Annonaceae) leaves and fruits on DMBA-induced breast cancer in female rats. BMC Complementary Medicine and Therapies.

4. Nana Tchoupang, E., Yadji, V., Wangbara, J. B., Kemegne Sipping, M. T., Zingue, S., Njamen, D., & Mutalik, S. (2022). In vitro and in vivo antiproliferative actions of Solanum gilo Raddi (Solanaceae) fruit extract on breast tissues. Advances in Pharmacological and Pharmaceutical Sciences.

5. Kamga Silihe, K., Zingue, S., Kemegne Sipping, M. T., Busuioc Cazanevscaia, A., Dediu Botezatu, A. V., Njamen, D., & Dinica, R. M. (2022). The antioxidant potential of Ficus umbellata Vahl (Moraceae) that accelerates in vitro and in vivo anti-inflammatory protective effects. Applied Sciences.

Paramanna Poojari | Pharmacology | Best Researcher Award

Published on by Health Scientists

Mr. Paramanna Poojari | Pharmacology | Best Researcher Award

Research Scholar | Karnatak University Dharwad | India

Dr. Paramanna Poojari, currently serving as a Research Scholar in the Department of Biochemistry at Karnatak University Dharwad, has built a strong academic and professional foundation in the fields of biochemistry, microbiology, nanotechnology, and cell culture. He holds a postgraduate degree in biochemistry and has specialized in experimental and applied research with a focus on nanoscience, cancer biology, drug delivery systems, and phytoremediation. Dr. Poojari’s research explores the potential of nanoparticles, plant tissue culture, antibiotic sensitivity testing, and nanomaterial characterization, with the objective of advancing innovative solutions for healthcare, pharmaceuticals, and environmental sustainability. His scholarly contributions include publications in highly regarded international journals indexed in Scopus, Google Scholar, and UGC CARE list, such as Drug Delivery Science and Technology, Water Air and Soil Pollution, and Dispersion Science and Technology, with a citation index of 24 and an h-index of 3. He has also contributed a book chapter published with ISBN: 9781032699882, further strengthening his academic profile. In recognition of his growing expertise, Dr. Poojari has been entrusted with editorial and peer-review responsibilities for reputed publishers including Elsevier and Springer Nature, underscoring his role in maintaining research quality and scientific integrity. His collaborations with nanotechnology laboratories have enabled interdisciplinary exploration bridging life sciences and material sciences. With patents under preparation and continued innovation in biotechnology applications, Dr. Poojari exemplifies a dedicated young scientist committed to impactful research. His academic achievements and professional contributions highlight his potential as a future leader in health sciences and allied fields. He has 18 citations from 8 documents with an h-index of 3.

Profile: Google Scholar | Scopus | ORCID

Publications

1. Ganeshkar, M. P., Gaddigal, A. T., Shivappa, P., Poojari, P. B., Goder, P. H., … (2023). Biocompatibility assessment of Rutin and PEG loaded novel nanoceria on human erythrocytes and human myeloid leukemia (U937) cells. Journal of Drug Delivery Science and Technology, 86, 104761.

2. Gaddigal, A. T., Shivappa, P., Ganeshkar, M. P., Mirjankar, M. R., Poojari, P. B., … (2024). Green synthesis of copper oxide nanoparticles using Simarouba glauca leaf extract, characterization and screening for their biological applications. Journal of Dispersion Science and Technology, 1–15.

3. Mirjankar, M. R., Pattar, S. V., Gaddigal, A. T., Shivappa, P., Poojari, P. B., … (2023). Phytoremediation of copper contaminated water using Pistia stratiotes and emphasis of thermal stability in response to metal stress. Water Conservation Science and Engineering, 8(1), 24.

4. Mirjankar, M. R., Pattar, S. V., Gaddigal, A. T., Shivappa, P., Poojari, P. B., … (2023). Isolation of culturable endophytic bacteria from the roots of Aloe vera L. (Aloe barbadensis Miller) and their application in phytodegradation of xenobiotics. Water, Air, & Soil Pollution, 234(7), 451.

5. Shivappa, P., Mirjankar, M. R., Gaddigal, A. T., Ganeshkar, M. P., Poojari, P. B., … (2023). Bismuth nanoparticle synthesis utilizing hydroalcoholic Endocomia macrocoma leaf extract to evaluate their antimicrobial, antioxidant, and anticancer properties. Journal of Dispersion Science and Technology, 1–15.